Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchMetforminMetformin (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

All Studies   Meta Analysis       

Does the Consumption of Metformin Correlate With a Reduction in Mortality Among Patients With Type 2 Diabetes and COVID-19 in Morocco?

Benfathallah et al., Cureus, doi:10.7759/cureus.77288
Jan 2025  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 54% Improvement Relative Risk Metformin  Benfathallah et al.  Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 115 patients in Morocco (August 2020 - August 2021) Lower mortality with metformin (p=0.041) c19early.org Benfathallah et al., Cureus, January 2025 Favorsmetformin Favorscontrol 0 0.5 1 1.5 2+
Metformin for COVID-19
3rd treatment shown to reduce risk in July 2020, now with p < 0.00000000001 from 104 studies.
No treatment is 100% effective. Protocols combine treatments.
5,300+ studies for 116 treatments. c19early.org
Retrospective 115 hospitalized type 2 diabetes patients in Morocco showing significantly lower mortality with metformin use.
risk of death, 53.6% lower, RR 0.46, p = 0.04, treatment 8 of 41 (19.5%), control 30 of 74 (40.5%), NNT 4.8, adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Benfathallah et al., 11 Jan 2025, retrospective, Morocco, peer-reviewed, mean age 65.5, 5 authors, study period 1 August, 2020 - 1 August, 2021. Contact: bouchra_benfathallah@um5.ac.ma.
This PaperMetforminAll
Does the Consumption of Metformin Correlate With a Reduction in Mortality Among Patients With Type 2 Diabetes and COVID-19 in Morocco?
Bouchra Benfathallah, Abha Cherkani Hassani, Samia El Hilali, Redouane Abouqal, Laïla Benchekroun
Cureus, doi:10.7759/cureus.77288
Objectives: To assess whether metformin therapy for type 2 diabetes (T2DM) was associated with a reduced mortality rate in patients hospitalized for COVID-19 compared to other antihyperglycemic drugs. Methods: This retrospective study included patients with T2DM who tested positive for SARS-CoV-2 between 1 August 2020 and 1 August 2021. The patients were required to be aged over 18 years old and to be undergoing treatment for hyperglycemia, whether with metformin, other oral antidiabetic drugs, or insulin. A data exploitation sheet was completed for each patient. The Jamovi ( https://www.jamovi.org/ ) software was applied to conduct the statistical analyses. Multivariate logistic regression was used to determine whether metformin use was associated with reduced mortality among patients with T2DM and COVID-19. Results: We identified 115 COVID-19 patients with T2DM, of whom 41 were on metformin, 35 patients were on insulin, and 39 patients were on other oral antihyperglycemic agents; the average age of patients was 65.5±13.2 years, and 52.2% were male. The mortality rate was lower in the metformin user group (21.1%) compared to the non-user group (78.9%). The multivariate logistic regression model indicated that age (OR=1.06; 95% CI (1.02-1.10); p=0.002) and glycemia (OR=1.49; 95% CI (1.05-2.11); p=0.024) were significantly associated with mortality in patients with T2DM and COVID-19. Whereas, the use of metformin was identified as a protective factor (OR=0.34 95% CI (0.12-0.95); p=0.041). Conclusion: This study highlighted that metformin seems to be associated with significantly decreased mortality in adults with T2DM and COVID-19.
Additional Information Author Contributions All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work. Concept and design: Bouchra Benfathallah, Abha Cherkani Hassani , Redouane Abouqal, Laïla Benchekroun Acquisition, analysis, or interpretation of data: Bouchra Benfathallah, Abha Cherkani Hassani , Samia El Hilali, Redouane Abouqal, Laïla Benchekroun Drafting of the manuscript: Bouchra Benfathallah, Laïla Benchekroun Critical review of the manuscript for important intellectual content: Bouchra Benfathallah, Abha Cherkani Hassani , Samia El Hilali, Redouane Abouqal, Laïla Benchekroun Supervision: Bouchra Benfathallah, Abha Cherkani Hassani , Samia El Hilali, Redouane Abouqal, Laïla Benchekroun Disclosures Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. The Ethics Committee of Biomedical Research (CERB) issued approval N/R: Dossier n°L/21. Data access and patient anonymity were respected according to national and international guidelines. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they..
References
Bornstein, Rubino, Khunti, Practical recommendations for the management of diabetes in patients with COVID-19, Lancet Diabetes Endocrinol, doi:10.1016/S2213-8587(20)30152-2
Bramante, Huling, Tignanelli, Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19, N Engl J Med, doi:10.1056/NEJMoa2201662
Bramante, Ingraham, Murray, Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis, Lancet Healthy Longev, doi:10.1016/S2666-7568(20)30033-7
Cao, Baranova, Wei, Wang, Zhang, Bidirectional causal associations between type 2 diabetes and COVID-19, J Med Virol, doi:10.1002/jmv.28100
Cao, Li, Tao, Metformin inhibits vascular calcification in female rat aortic smooth muscle cells via the AMPK-eNOS-NO pathway, Endocrinol, doi:10.1210/en.2013-1002
Cheng, Xin, Chen, Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: a multicentral retrospective study, Life Sci, doi:10.1016/j.lfs.2021.119371
Erickson, Fenno, Barzilai, Metformin for treatment of acute COVID-19: systematic review of clinical trial data against SARS-CoV-2, Diabetes Care, doi:10.2337/dc22-2539
Fang, Karakiulakis, Roth, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?, Lancet Respir Med, doi:10.1016/S2213-2600(20)30116-8
Gallo Marin, Aghagoli, Lavine, Predictors of COVID-19 severity: a literature review, Rev Med Virol, doi:10.1002/rmv.2146
Gao, Liu, Zhong, Liu, Zhou et al., Risk of metformin in patients with type 2 diabetes with COVID-19: a preliminary retrospective report, Clin Transl Sci, doi:10.1111/cts.12897
Ghany, Palacio, Dawkins, Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA, Diabetes Metab Syndr, doi:10.1016/j.dsx.2021.02.022
Hariyanto, Kurniawan, Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection, Obes Med, doi:10.1016/j.obmed.2020.100290
Holman, Knighton, Kar, Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study, Lancet Diabetes Endocrinol, doi:10.1016/S2213-8587(20)30271-0
Kaneto, Kimura, Obata, Shimoda, Kaku, Multifaceted mechanisms of action of metformin which have been unraveled one after another in the long history, Int J Mol Sci, doi:10.3390/ijms22052596
Lalau, Al-Salameh, Hadjadj, Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19, Diabetes Metab, doi:10.1016/j.diabet.2020.101216
Li, Yang, Yan, Sun, Zeng et al., Metformin in patients with COVID-19: a systematic review and meta-analysis, Front Med, doi:10.3389/fmed.2021.704666
Lukito, Pranata, Henrina, Lim, Lawrensia et al., The effect of metformin consumption on mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.11.006
Luo, Qiu, Liu, Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis, Am J Trop Med Hyg, doi:10.4269/ajtmh.20-0375
Ma, Krishnamurthy, Is metformin use associated with low mortality in patients with type 2 diabetes mellitus hospitalized for COVID-19? a multivariable and propensity score-adjusted meta-analysis, PLoS One, doi:10.1371/journal.pone.0282210
Malhotra, Hepokoski, Mccowen, Shyy, ACE2, metformin, and COVID-19, Iscience
Samuel, Varghese, Büsselberg, Therapeutic potential of metformin in COVID-19: reasoning for its protective role, Trends Microbiol, doi:10.1016/j.tim.2021.03.004
Sharma, Ray, Sadasivam, Metformin in COVID-19: a possible role beyond diabetes, Diabetes Res Clin Pract, doi:10.1016/j.diabres.2020.108183
Silverii, Fumagalli, Rozzini, Milani, Mannucci et al., Is metformin use associated with a more favorable Covid-19 course in people with diabetes?, J Clin Med, doi:10.3390/jcm13071874
Singh, Singh, Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?, Diabetes Res Clin Pract, doi:10.1016/j.diabres.2020.108268
Song, Zhang, Meng, Mechanism and application of metformin in kidney diseases: an update, Biomed Pharmacother, doi:10.1016/j.biopha.2021.111454
Tong, Grant, Gras, The role of T-cell immunity in COVID-19 severity amongst people living with type II diabetes, FEBS J, doi:10.1111/febs.16105
Wang, Cooper, Gokhale, Association of metformin with susceptibility to COVID-19 in people with type 2 diabetes, J Clin Endocrinol Metab, doi:10.1210/clinem/dgab067
Wang, Lin, Sy, Renal protective effect of metformin in type 2 diabetes patients, J Clin Endocrinol Metab, doi:10.1210/clinem/dgae477
Watson, Dhaliwal, Robertshaw, Consensus recommendations for sick day medication guidance for people with diabetes, kidney, or cardiovascular disease: a modified Delphi process, Am J Kidney Dis, doi:10.1053/j.ajkd.2022.10.012
Wiernsperger, Al-Salameh, Cariou, Lalau, Protection by metformin against severe COVID-19: an in-depth mechanistic analysis, Diabetes Metab, doi:10.1016/j.diabet.2022.101359
Zumla, Hui, Azhar, Memish, Maeurer, Reducing mortality from 2019-nCoV: host-directed therapies should be an option, Lancet, doi:10.1016/S0140-6736(20)30305-6
DOI record: { "DOI": "10.7759/cureus.77288", "ISSN": [ "2168-8184" ], "URL": "http://dx.doi.org/10.7759/cureus.77288", "author": [ { "affiliation": [], "family": "Benfathallah", "given": "Bouchra", "sequence": "first" }, { "affiliation": [], "family": "Cherkani Hassani", "given": "Abha", "sequence": "additional" }, { "affiliation": [], "family": "El Hilali", "given": "Samia", "sequence": "additional" }, { "affiliation": [], "family": "Abouqal", "given": "Redouane", "sequence": "additional" }, { "affiliation": [], "family": "Benchekroun", "given": "Laïla", "sequence": "additional" } ], "container-title": "Cureus", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2025, 1, 11 ] ], "date-time": "2025-01-11T17:55:46Z", "timestamp": 1736618146000 }, "deposited": { "date-parts": [ [ 2025, 1, 11 ] ], "date-time": "2025-01-11T17:55:48Z", "timestamp": 1736618148000 }, "indexed": { "date-parts": [ [ 2025, 1, 12 ] ], "date-time": "2025-01-12T05:21:46Z", "timestamp": 1736659306657, "version": "3.32.0" }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2025, 1, 11 ] ] }, "language": "en", "link": [ { "URL": "https://www.cureus.com/articles/325967-does-the-consumption-of-metformin-correlate-with-a-reduction-in-mortality-among-patients-with-type-2-diabetes-and-covid-19-in-morocco", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.7759", "published": { "date-parts": [ [ 2025, 1, 11 ] ] }, "published-print": { "date-parts": [ [ 2025, 1, 11 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1111/febs.16105", "article-title": "The role of T-cell immunity in COVID-19 severity amongst people living with type II diabetes", "author": "Tong ZW", "doi-asserted-by": "publisher", "journal-title": "FEBS J", "key": "ref1", "unstructured": "Tong ZW, Grant E, Gras S, et al.. The role of T-cell immunity in COVID-19 severity amongst people living with type II diabetes. FEBS J. 2021, 288:5042-54. 10.1111/febs.16105", "volume": "288", "year": "2021" }, { "DOI": "10.1016/S2213-8587(20)30271-0", "article-title": "Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study", "author": "Holman N", "doi-asserted-by": "publisher", "journal-title": "Lancet Diabetes Endocrinol", "key": "ref2", "unstructured": "Holman N, Knighton P, Kar P, et al.. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020, 8:823-33. 10.1016/S2213-8587(20)30271-0", "volume": "8", "year": "2020" }, { "DOI": "10.1016/S2213-2600(20)30116-8", "article-title": "Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?", "author": "Fang L", "doi-asserted-by": "publisher", "journal-title": "Lancet Respir Med", "key": "ref3", "unstructured": "Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med. 2020, 8:e21. 10.1016/S2213-2600(20)30116-8", "volume": "8", "year": "2020" }, { "DOI": "10.1002/jmv.28100", "article-title": "Bidirectional causal associations between type 2 diabetes and COVID-19", "author": "Cao H", "doi-asserted-by": "publisher", "journal-title": "J Med Virol", "key": "ref4", "unstructured": "Cao H, Baranova A, Wei X, Wang C, Zhang F. Bidirectional causal associations between type 2 diabetes and COVID-19. J Med Virol. 2023, 95:e28100. 10.1002/jmv.28100", "volume": "95", "year": "2023" }, { "DOI": "10.1210/clinem/dgab067", "article-title": "Association of metformin with susceptibility to COVID-19 in people with type 2 diabetes", "author": "Wang J", "doi-asserted-by": "publisher", "journal-title": "J Clin Endocrinol Metab", "key": "ref5", "unstructured": "Wang J, Cooper JM, Gokhale K, et al.. Association of metformin with susceptibility to COVID-19 in people with type 2 diabetes. J Clin Endocrinol Metab. 2021, 106:1255-68. 10.1210/clinem/dgab067", "volume": "106", "year": "2021" }, { "DOI": "10.3390/jcm13071874", "article-title": "Is metformin use associated with a more favorable Covid-19 course in people with diabetes?", "author": "Silverii GA", "doi-asserted-by": "publisher", "journal-title": "J Clin Med", "key": "ref6", "unstructured": "Silverii GA, Fumagalli C, Rozzini R, Milani M, Mannucci E, Marchionni N. Is metformin use associated with a more favorable Covid-19 course in people with diabetes?. J Clin Med. 2024, 13:1874. 10.3390/jcm13071874", "volume": "13", "year": "2024" }, { "DOI": "10.2337/dc22-2539", "article-title": "Metformin for treatment of acute COVID-19: systematic review of clinical trial data against SARS-CoV-2", "author": "Erickson SM", "doi-asserted-by": "publisher", "journal-title": "Diabetes Care", "key": "ref7", "unstructured": "Erickson SM, Fenno SL, Barzilai N, et al.. Metformin for treatment of acute COVID-19: systematic review of clinical trial data against SARS-CoV-2. Diabetes Care. 2023, 46:1432-42. 10.2337/dc22-2539", "volume": "46", "year": "2023" }, { "DOI": "10.1016/S2666-7568(20)30033-7", "article-title": "Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis", "author": "Bramante CT", "doi-asserted-by": "publisher", "journal-title": "Lancet Healthy Longev", "key": "ref8", "unstructured": "Bramante CT, Ingraham NE, Murray TA, et al.. Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. Lancet Healthy Longev. 2021, 2:e34-41. 10.1016/S2666-7568(20)30033-7", "volume": "2", "year": "2021" }, { "DOI": "10.1371/journal.pone.0282210", "article-title": "Is metformin use associated with low mortality in patients with type 2 diabetes mellitus hospitalized for COVID-19? a multivariable and propensity score-adjusted meta-analysis", "author": "Ma Z", "doi-asserted-by": "publisher", "journal-title": "PLoS One", "key": "ref9", "unstructured": "Ma Z, Krishnamurthy M. Is metformin use associated with low mortality in patients with type 2 diabetes mellitus hospitalized for COVID-19? a multivariable and propensity score-adjusted meta-analysis. PLoS One. 2023, 18:e0282210. 10.1371/journal.pone.0282210", "volume": "18", "year": "2023" }, { "DOI": "10.3389/fmed.2021.704666", "article-title": "Metformin in patients with COVID-19: a systematic review and meta-analysis", "author": "Li Y", "doi-asserted-by": "publisher", "journal-title": "Front Med (Lausanne)", "key": "ref10", "unstructured": "Li Y, Yang X, Yan P, Sun T, Zeng Z, Li S. Metformin in patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021, 8:704666. 10.3389/fmed.2021.704666", "volume": "8", "year": "2021" }, { "DOI": "10.1016/j.diabet.2020.101216", "article-title": "Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19", "author": "Lalau JD", "doi-asserted-by": "publisher", "journal-title": "Diabetes Metab", "key": "ref11", "unstructured": "Lalau JD, Al-Salameh A, Hadjadj S, et al.. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes Metab. 2021, 47:101216. 10.1016/j.diabet.2020.101216", "volume": "47", "year": "2021" }, { "DOI": "10.4269/ajtmh.20-0375", "article-title": "Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis", "author": "Luo P", "doi-asserted-by": "publisher", "journal-title": "Am J Trop Med Hyg", "key": "ref12", "unstructured": "Luo P, Qiu L, Liu Y, et al.. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am J Trop Med Hyg. 2020, 103:69-72. 10.4269/ajtmh.20-0375", "volume": "103", "year": "2020" }, { "DOI": "10.1016/j.lfs.2021.119371", "article-title": "Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: a multicentral retrospective study", "author": "Cheng X", "doi-asserted-by": "publisher", "journal-title": "Life Sci", "key": "ref13", "unstructured": "Cheng X, Xin S, Chen Y, et al.. Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: a multicentral retrospective study. Life Sci. 2021, 275:119371. 10.1016/j.lfs.2021.119371", "volume": "275", "year": "2021" }, { "DOI": "10.1016/S2213-8587(20)30152-2", "article-title": "Practical recommendations for the management of diabetes in patients with COVID-19", "author": "Bornstein SR", "doi-asserted-by": "publisher", "journal-title": "Lancet Diabetes Endocrinol", "key": "ref14", "unstructured": "Bornstein SR, Rubino F, Khunti K, et al.. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020, 8:546-50. 10.1016/S2213-8587(20)30152-2", "volume": "8", "year": "2020" }, { "DOI": "10.1016/j.diabres.2020.108268", "article-title": "Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?", "author": "Singh AK", "doi-asserted-by": "publisher", "journal-title": "Diabetes Res Clin Pract", "key": "ref15", "unstructured": "Singh AK, Singh R. Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?. Diabetes Res Clin Pract. 2020, 165:108268. 10.1016/j.diabres.2020.108268", "volume": "165", "year": "2020" }, { "DOI": "10.1016/j.diabres.2020.108183", "article-title": "Metformin in COVID-19: a possible role beyond diabetes", "author": "Sharma S", "doi-asserted-by": "publisher", "journal-title": "Diabetes Res Clin Pract", "key": "ref16", "unstructured": "Sharma S, Ray A, Sadasivam B. Metformin in COVID-19: a possible role beyond diabetes. Diabetes Res Clin Pract. 2020, 164:108183. 10.1016/j.diabres.2020.108183", "volume": "164", "year": "2020" }, { "DOI": "10.1002/rmv.2146", "article-title": "Predictors of COVID-19 severity: a literature review", "author": "Gallo Marin B", "doi-asserted-by": "publisher", "journal-title": "Rev Med Virol", "key": "ref17", "unstructured": "Gallo Marin B, Aghagoli G, Lavine K, et al.. Predictors of COVID-19 severity: a literature review. Rev Med Virol. 2021, 31:1-10. 10.1002/rmv.2146", "volume": "31", "year": "2021" }, { "DOI": "10.1016/j.tim.2021.03.004", "article-title": "Therapeutic potential of metformin in COVID-19: reasoning for its protective role", "author": "Samuel SM", "doi-asserted-by": "publisher", "journal-title": "Trends Microbiol", "key": "ref18", "unstructured": "Samuel SM, Varghese E, Büsselberg D. Therapeutic potential of metformin in COVID-19: reasoning for its protective role. Trends Microbiol. 2021, 29:894-907. 10.1016/j.tim.2021.03.004", "volume": "29", "year": "2021" }, { "DOI": "10.1210/clinem/dgae477", "article-title": "Renal protective effect of metformin in type 2 diabetes patients", "author": "Wang HH", "doi-asserted-by": "publisher", "journal-title": "J Clin Endocrinol Metab", "key": "ref19", "unstructured": "Wang HH, Lin SH, Hung SY, et al.. Renal protective effect of metformin in type 2 diabetes patients. J Clin Endocrinol Metab. 2024, 477. 10.1210/clinem/dgae477", "year": "2024" }, { "DOI": "10.1016/j.biopha.2021.111454", "article-title": "Mechanism and application of metformin in kidney diseases: an update", "author": "Song A", "doi-asserted-by": "publisher", "journal-title": "Biomed Pharmacother", "key": "ref20", "unstructured": "Song A, Zhang C, Meng X. Mechanism and application of metformin in kidney diseases: an update. Biomed Pharmacother. 2021, 138:111454. 10.1016/j.biopha.2021.111454", "volume": "138", "year": "2021" }, { "DOI": "10.1016/j.dsx.2020.11.006", "article-title": "The effect of metformin consumption on mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis", "author": "Lukito AA", "doi-asserted-by": "publisher", "journal-title": "Diabetes Metab Syndr", "key": "ref21", "unstructured": "Lukito AA, Pranata R, Henrina J, Lim MA, Lawrensia S, Suastika K. The effect of metformin consumption on mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. Diabetes Metab Syndr. 2020, 14:2177-83. 10.1016/j.dsx.2020.11.006", "volume": "14", "year": "2020" }, { "DOI": "10.1016/j.dsx.2021.02.022", "article-title": "Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA", "author": "Ghany R", "doi-asserted-by": "publisher", "journal-title": "Diabetes Metab Syndr", "key": "ref22", "unstructured": "Ghany R, Palacio A, Dawkins E, et al.. Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA. Diabetes Metab Syndr. 2021, 15:513-8. 10.1016/j.dsx.2021.02.022", "volume": "15", "year": "2021" }, { "DOI": "10.1111/cts.12897", "article-title": "Risk of metformin in patients with type 2 diabetes with COVID-19: a preliminary retrospective report", "author": "Gao Y", "doi-asserted-by": "publisher", "journal-title": "Clin Transl Sci", "key": "ref23", "unstructured": "Gao Y, Liu T, Zhong W, Liu R, Zhou H, Huang W, Zhang W. Risk of metformin in patients with type 2 diabetes with COVID-19: a preliminary retrospective report. Clin Transl Sci. 2020, 13:1055-9. 10.1111/cts.12897", "volume": "13", "year": "2020" }, { "DOI": "10.1056/NEJMoa2201662", "article-title": "Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19", "author": "Bramante CT", "doi-asserted-by": "publisher", "journal-title": "N Engl J Med", "key": "ref24", "unstructured": "Bramante CT, Huling JD, Tignanelli CJ, et al.. Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19. N Engl J Med. 2022, 387:599-610. 10.1056/NEJMoa2201662", "volume": "387", "year": "2022" }, { "DOI": "10.1053/j.ajkd.2022.10.012", "article-title": "Consensus recommendations for sick day medication guidance for people with diabetes, kidney, or cardiovascular disease: a modified Delphi process", "author": "Watson KE", "doi-asserted-by": "publisher", "journal-title": "Am J Kidney Dis", "key": "ref25", "unstructured": "Watson KE, Dhaliwal K, Robertshaw S, et al.. Consensus recommendations for sick day medication guidance for people with diabetes, kidney, or cardiovascular disease: a modified Delphi process. Am J Kidney Dis. 2023, 81:564-74. 10.1053/j.ajkd.2022.10.012", "volume": "81", "year": "2023" }, { "DOI": "10.1016/j.isci.2020.101425", "article-title": "ACE2, metformin, and COVID-19", "author": "Malhotra A", "doi-asserted-by": "crossref", "journal-title": "Iscience", "key": "ref26", "unstructured": "Malhotra A, Hepokoski M, McCowen KC, Shyy JY. ACE2, metformin, and COVID-19. Iscience. 2020, 23:", "volume": "23", "year": "2020" }, { "DOI": "10.3390/ijms22052596", "article-title": "Multifaceted mechanisms of action of metformin which have been unraveled one after another in the long history", "author": "Kaneto H", "doi-asserted-by": "publisher", "journal-title": "Int J Mol Sci", "key": "ref27", "unstructured": "Kaneto H, Kimura T, Obata A, Shimoda M, Kaku K. Multifaceted mechanisms of action of metformin which have been unraveled one after another in the long history. Int J Mol Sci. 2021, 22:2596. 10.3390/ijms22052596", "volume": "22", "year": "2021" }, { "DOI": "10.1016/j.obmed.2020.100290", "article-title": "Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection", "author": "Hariyanto TI", "doi-asserted-by": "publisher", "journal-title": "Obes Med", "key": "ref28", "unstructured": "Hariyanto TI, Kurniawan A. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection. Obes Med. 2020, 19:100290. 10.1016/j.obmed.2020.100290", "volume": "19", "year": "2020" }, { "DOI": "10.1016/j.diabet.2022.101359", "article-title": "Protection by metformin against severe COVID-19: an in-depth mechanistic analysis", "author": "Wiernsperger N", "doi-asserted-by": "publisher", "journal-title": "Diabetes Metab", "key": "ref29", "unstructured": "Wiernsperger N, Al-Salameh A, Cariou B, Lalau JD. Protection by metformin against severe COVID-19: an in-depth mechanistic analysis. Diabetes Metab. 2022, 48:101359. 10.1016/j.diabet.2022.101359", "volume": "48", "year": "2022" }, { "DOI": "10.1210/en.2013-1002", "article-title": "Metformin inhibits vascular calcification in female rat aortic smooth muscle cells via the AMPK-eNOS-NO pathway", "author": "Cao X", "doi-asserted-by": "publisher", "journal-title": "Endocrinol", "key": "ref30", "unstructured": "Cao X, Li H, Tao H, et al.. Metformin inhibits vascular calcification in female rat aortic smooth muscle cells via the AMPK-eNOS-NO pathway. Endocrinol. 2013, 154:3680-9. 10.1210/en.2013-1002", "volume": "154", "year": "2013" }, { "DOI": "10.1016/S0140-6736(20)30305-6", "article-title": "Reducing mortality from 2019-nCoV: host-directed therapies should be an option", "author": "Zumla A", "doi-asserted-by": "publisher", "journal-title": "Lancet", "key": "ref31", "unstructured": "Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020, 395:e35-6. 10.1016/S0140-6736(20)30305-6", "volume": "395", "year": "2020" } ], "reference-count": 31, "references-count": 31, "relation": {}, "resource": { "primary": { "URL": "https://www.cureus.com/articles/325967-does-the-consumption-of-metformin-correlate-with-a-reduction-in-mortality-among-patients-with-type-2-diabetes-and-covid-19-in-morocco" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Does the Consumption of Metformin Correlate With a Reduction in Mortality Among Patients With Type 2 Diabetes and COVID-19 in Morocco?", "type": "journal-article" }
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit